普洛药业(000739.SZ)：左卡尼汀注射液获得药品注册证书

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for L-Carnitine Injection from the National Medical Products Administration, indicating a significant advancement in its product portfolio [1] Company Summary - Pro Pharmaceutical's subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., is the entity that received the drug registration certificate [1] - The newly approved L-Carnitine Injection is intended for patients with chronic renal failure undergoing long-term hemodialysis, addressing secondary carnitine deficiency and its associated complications [1] Industry Summary - The approval of L-Carnitine Injection highlights the growing focus on treatments for chronic kidney disease and related conditions, which is a critical area in the pharmaceutical industry [1] - The clinical manifestations targeted by this product include cardiomyopathy, skeletal muscle disease, arrhythmias, hyperlipidemia, hypotension, and muscle cramps during dialysis [1]